Tidutamab

N/A

Report date: 2026/03/19 16:46:21

Base Information

Drug NameTidutamab

Drug Alias NameXmAb-18087

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionSomatostatin receptor 2 antagonistsT cell surface glycoprotein CD3 inhibitors

TargetsT cell surface glycoprotein CD3Somatostatin receptor 2

Therapy Area/IndicationsSmall Cell Lung CarcinomaCarcinoma, Merkel Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesXencor Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesXencor Inc

Active IndicationsN/A

Inactive IndicationsSmall Cell Lung CarcinomaCarcinoma, Merkel Cell

Other Information

ATC CodeN/A